Expanesthetics is using groundbreaking technology to develop new inhaled anesthetics with fewer side effects. Nearly 100 anesthesia clinicians have collectively invested over $5 million. Now, you can be part of the most exciting innovation in anesthesia.
Our market research shows anesthesia clinicians want the kinds of agents we're developing — agents with fewer side effects.
The general anesthetic market is about $2 billion per year, and new agents have historically achieved long exclusivity.
Inhaled general anesthetics are unusual in pharma — they work similarly across all species. That may mean less translation risk.
Five billion people lack access to safe surgical and anesthesia care. New agents with fewer side effects could help.
Our development pipeline has already found anesthetic candidates with better cardiovascular performance. Now we're ready to scale up our screening technology to identify a candidate to advance into first-in-human trials (our targeted M&A milestone) in about 3 years.
Our management team are leaders at the forefront of inhaled anesthetic development. Our Board of Directors has executive leadership experience in both small and large, public and private organizations, including enterprises with billions of dollars of assets and revenue. Our scientific and clinical advisory boards include well-known experts with a diverse range of experience, knowledge, and networks.
"As an acute pain and regional anesthesiologist, my practice focuses on advancing clinical anesthesia. I joined the Expanesthetics team as a shareholder because I see the potential for the technology to create incredibly positive change not only for my practice, but for the practice of anesthesia around the world."
* This is not an offer to sell or a solicitation of any offer to buy any securities. Offers are made only by prospectus or other offering materials. Only prospective investors who have been invited to review such materials and meet the suitability standards required by law are eligible to invest. This website includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Expanesthetics’ management and are subject to significant risks and uncertainties. There can be no guarantees. These statements are made as of the date of this communication and Expanesthetics assumes no obligation to provide updates.